Respiratorius: Cadila Pharmaceuticals signs agreement with Respiratorius: To develop novel solutions for COPD and Asthma jointly

Read news item from Respiratorius

Sweden-based Respiratorius AB (publ) and Cadila Pharmaceuticals Ltd., one of India’s largest privately held pharmaceuticals companies, have signed an agreement to develop drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and Asthma. The collaboration includes preclinical and clinical development of drug candidates from the RESP-1000 series, at Cadila Pharmaceuticals’ state-of-the-art research and development facility at Ahmedabad, Gujarat, India.

Post Phase II completion, Cadila Pharmaceuticals Ltd. will acquire the rights to Respiratorius’ patents for RESP-1000 series in territories like Africa, the Middle East and Asia, while Respiratorius will retain rights in Europe and the United States, China and Japan. The development will be in accordance with EU-GMP and guidelines of the European Medicines Agency.

The partnership agreement also defines the distribution of the potential revenue in respective territories. Respiratorius will receive a percentage of royalty revenues from future net revenue from all sales in Cadila Pharmaceuticals’ territories. The royalty rate for Respiratorius is in single digit and in the lower region. Similarly, future revenues, such as milestone payments and royalties in Respiratorius’ territories would be divided between the parties. Respiratorius will then receive more than two-thirds of all revenues from third parties.

Cadila Pharmaceuticals, with its significant experience and success in developing many first-in-the–world innovative products, like Polycap (5-in-1 pill for prevention and treatment of cardiovascular diseases), Risorine (Innovative solution for treatment of Tuberculosis) and the recently introduced Mycidac- C, which is the world’s first active immunotherapy in lung cancer, will further deploy resources and expertise in this drug development.

"The agreement with Cadila Pharmaceuticals is extremely important as it allows for Respiratorius to complete development of the RESP-1000 series which is designed for the extremely large group of COPD patients, a patient population that is currently lacking effective treatment," says Respiratorius CEO, Johan Drott. He further said:"Cadila Pharmaceuticals is one of the very few Indian companies that have produced a number of successful original preparations for the American and European market and is therefore an ideal partner at this stage.”

Speaking on this collaboration, Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals said: “Cadila Pharmaceuticals’ foundation is built on research and innovation. This partnership with Respiratorius evolves from our vision to partner with leading global research institutions to find novel, innovative and affordable solutions for unmet medical needs. Respiratory medicine is one of our key focus therapy areas and we have had great success with Risorine, the world’s first innovative solution with boosted Rifampicin and bioenhancer for treatment of Tuberculosis. COPD and Asthma, which are debilitating diseases and hamper quality of life, will stand to benefit from this venture.”

RESP-1000 Series is an innovative, patented chemical series (NCE) that has demonstrated groundbreaking ability to relax small human bronchus in a series of experiments on isolated lung tissue human. Unlike the other drugs in the market, RESP-1000 provides complete relaxation of the smallest bronchi. This is especially important for COPD patients because the disease is characterized by a sharp narrowing of the small bronchi, combined with the destruction of the alveoli.


For further information, please contact:

Johan Drott, CEO, Respiratorius
johan.drott@respiratorius.com

Neelam Kanwar, Head - Corporate Communications and CSR, Cadila Pharmaceuticals Limited.
Phone: +91-2718-225001-15 Ext: 1423 or +91 9099099624
neelam.kanwar@cadilapharma.co.in


TO THE EDITORS

About Respiratorius (www.respiratorius.com)
Respiratorius AB develops new and effective candidate drugs for treatment of cancer, COPD and asthma. The project portfolio also includes development of a biomarker for cardiovascular PET-imaging. The oncology drug project (VAL-001) is currently in clinical phase I for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the company has developed two new classes of proprietary drug substances (RESP-1000 and RESP-2000 series), which compared to current practices have superior bronchodilating effect on small airways. These substances, which utilize new methods of action, are developed in ex-vivo experiments on human lung tissue with the RESP-HSAT technology platform.

Respiratorius was founded in 1999 as a research spin-out from Lund University. Since 2012, Respiratorius is a public company listed on the Equities Market Place (Aktietorget.)


About Cadila Pharmaceuticals (www.cadilapharma.com)
Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures world-class, quality pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular. Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world. Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.


Read news item from Respiratorius  Further information about Respiratorius

Publicerat: 10/3/2014 8:01:58 AM

Nyheten distribueras av AktieTorget i samarbete med Cision.
För att prenumerera på nyheter på detta bolag, klicka här.
 

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se